Before we can fully take advantage of antisense therapeutics, we first need to effectively deliver the RNAi agent to its target. When it comes to oligonucleotides, says Dr Catherine McKeen, there are many challenges surrounding drug delivery – but with many strategies in development, the future looks bright.
Article published in Laboratory News, November 2014. Available to read online.
Related products: 2163, 2170, 2189, 2194, 2199, 2393, 2394 and 2530.